Literature DB >> 15254676

Distribution of the extracellular matrix glycoproteins in ependymomas--an immunohistochemical study with follow-up analysis.

J Zámecník1, M Chánová, M Tichý, R Kodet.   

Abstract

The extracellular matrix (ECM) plays a critical role in influencing the biological behavior of brain tumors and the diagnostic detection of ECM components in ependymomas might be of prognostic value. In the present study we evaluated immunohistochemically the expression of a spectrum of ECM glycoproteins (tenascin, vitronectin, fibronectin, laminin, collagen types II, IV and VI) in a series of 36 pediatric intracranial ependymomas. The distribution of the ECM glycoproteins was evaluated both within the tumor tissue and at the tumor invasion front, and the prognostic value of the results was tested in a survival analysis. The expression of most of the ECM glycoproteins was associated only with blood vessels. Tenascin and vitronectin were found in a more diffuse pattern around the tumor cells and at the tumor invasion fronts of several cases. The progression-free survival was significantly decreased for patients with tenascin positive tumors (in any of the studied compartments) and for the tumors with vitronectin accumulation at their invasion fronts. In one ependymoma containing foci of cartilage with metaplastic ossification we demonstrated that collagen types II and VI and tenascin were present in ECM of both the cartilage and the ependymoma, and were accompanied by areas of necrosis and dystrophic calcifications. We suggest, that the rare simultaneous production of the specific ECM components might lead to the formation of chondroid areas in ependymomas. An abundant production of some ECM glycoproteins (tenascin and vitronectin) is present in a proportion of ependymomas and its immunohistochemical detection is of prognostic relevance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15254676

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  6 in total

Review 1.  Immunohistochemical prognostic markers in intracranial ependymomas: systematic review and meta-analysis.

Authors:  Klara Kuncova; Ales Janda; Pavel Kasal; Josef Zamecnik
Journal:  Pathol Oncol Res       Date:  2009-03-20       Impact factor: 3.201

2.  Cartilage differentiation in ependymoma: histogenetic considerations on a new case.

Authors:  Antonella Coli; Mariangela Novello; Luca Massimi; Massimo Caldarelli; Valentina Ranucci; Libero Lauriola
Journal:  Childs Nerv Syst       Date:  2014-01-22       Impact factor: 1.475

3.  Clinical significance of serum tenascin-c levels in epithelial ovarian cancer.

Authors:  Tastekin Didem; Tas Faruk; Karabulut Senem; Duranyildiz Derya; Serilmez Murat; Guveli Murat; Kaynur Oznur
Journal:  Tumour Biol       Date:  2014-04-11

4.  Tenascin-C enhances pancreatic cancer cell growth and motility and affects cell adhesion through activation of the integrin pathway.

Authors:  Igor Paron; Sonja Berchtold; Julia Vörös; Madhavi Shamarla; Mert Erkan; Heinz Höfler; Irene Esposito
Journal:  PLoS One       Date:  2011-06-29       Impact factor: 3.240

5.  Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.

Authors:  Asuka Araki; Monika Chocholous; Johannes Gojo; Christian Dorfer; Thomas Czech; Harald Heinzl; Karin Dieckmann; Inge M Ambros; Peter F Ambros; Irene Slavc; Christine Haberler
Journal:  Acta Neuropathol Commun       Date:  2016-08-22       Impact factor: 7.801

6.  Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification.

Authors:  Felipe Andreiuolo; Gwénaël Le Teuff; Mohamed Amine Bayar; John-Paul Kilday; Torsten Pietsch; André O von Bueren; Hendrik Witt; Andrey Korshunov; Piergiorgio Modena; Stefan M Pfister; Mélanie Pagès; David Castel; Felice Giangaspero; Leila Chimelli; Pascale Varlet; Stefan Rutkowski; Didier Frappaz; Maura Massimino; Richard Grundy; Jacques Grill
Journal:  PLoS One       Date:  2017-06-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.